200 years after James Parkinson's An Essay on the Shaking Palsy, 2017 has seen important advances that are driving a shift towards a broader and more holistic understanding of Parkinson disease aetiology and progression. This shift might finally pave the way to entirely novel and more effective prevention and management strategies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regulation of common neurological disorders by gut microbial metabolites
Experimental & Molecular Medicine Open Access 02 December 2021
-
Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease
Microbiome Open Access 31 January 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Obeso, J. A. et al. Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov. Disord. 32, 1264–1310 (2017).
Espay, A. J. et al. Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319–324 (2017).
Mass, E. et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature 549, 389–393 (2017).
Witoelar, A. et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780–792 (2017).
Pilotto, A. et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov. Disord. 32, 1025–1034 (2017).
Fereshtehnejad, S.-M. et al. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain 140, 1959–1976 (2017).
van Uem, J. et al. Health-related quality of life in patients with Parkinson's disease — a systematic review based on the ICF model. Neurosci. Biobehav. Rev. 61, 26–34 (2016).
Henderson, E. J. et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Neurol. 15, 249–258 (2016).
Nieuwhof, F. et al. Impaired dual tasking in Parkinson's disease is associated with reduced focusing of cortico-striatal activity. Brain 140, 1384–1398 (2017).
Mittal, S. et al. β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357, 891–898 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Maetzler, W., Berg, D. Changing views after 200 years of Parkinson disease. Nat Rev Neurol 14, 70–72 (2018). https://doi.org/10.1038/nrneurol.2017.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.183
This article is cited by
-
Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease
Microbiome (2021)
-
Regulation of common neurological disorders by gut microbial metabolites
Experimental & Molecular Medicine (2021)